Xanadu Quantum Technologies Inc. has published a computational framework on arXiv demonstrating how fault-tolerant quantum computers can model the transition properties of photosensitizers used in photodynamic therapy (PDT). The research addresses the computational bottleneck in simulating the light-activated compounds required to selectively induce tumor cell apoptosis. By applying quantum simulation algorithms to four structurally diverse photosensitizers, the framework identifies specific pathways for determining intersystem crossing rates and cumulative absorption from first principles.
The proposed quantum-based workflow focuses on simulating critical electronic state transitions that are fundamentally challenging for classical approximations, particularly in highly coupled electronic systems. Xanadu’s framework provides resource estimates for executing these algorithms on utility-scale hardware, projecting significant reductions in simulation runtime compared to leading classical methods. This capability is essential for identifying photosensitizer candidates that can highly efficiently generate the reactive oxygen species necessary for effective PDT.
This research serves as a foundational step toward a broader quantum drug-discovery pipeline, with Xanadu planning to extend the framework to more complex molecular architectures. The announcement coincides with Xanadu’s planned business combination with Crane Harbor Acquisition Corp. (Nasdaq: CHAC), which is expected to capitalize the company with approximately US$500 million. CEO Christian Weedbrook positions these developments as part of a 2026 industry pivot toward early commercial feasibility in quantum chemistry and mission-driven public-private deployments.
Read the full announcement here and the research paper can be found here.
December 19, 2025
Leave A Comment